Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452985
Status:
COMPLETED
Last Update Posted:
2012-08-14
First Post:
2007-03-27
Brief Title:
Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
Randomised Study With Docetaxel Cisplatin and Cyclophosphamide vs Docetaxel and Carboplatin as First Line Chemotherapy With Advanced or Metastatic Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OCSTUD
Brief Summary:
Primary objective
To assess response rate To record the clinical improvement in relation to stage and histopathological grading
Secondary objective
To determine progression free survival To find out overall survival To evaluate the safety of the study regimen
To assess response rate To record the clinical improvement in relation to stage and histopathological grading
Secondary objective
To determine progression free survival To find out overall survival To evaluate the safety of the study regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None